In addition, the ARPC5 high-expression group was associated with poor overall survival compared to that in the ARPC5 low-expression group, and multivariable analysis indicated that ARPC5 was an independent prognostic factor in patients with multiple myeloma (MM) (Xiong and Luo, 2018). Here, ARPC5 is linked to AL amyloidosis.